RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

被引：131

作者：

Wen, Patrick Y. ^{[1
,2
]}

van den Bent, Martin ^{[3
]}

Youssef, Gilbert ^{[1
,2
]}

Cloughesy, Timothy F. ^{[4
]}

Ellingson, Benjamin M. ^{[5
]}

Weller, Michael ^{[6
,7
]}

Galanis, Evanthia ^{[8
]}

Barboriak, Daniel P. ^{[9
]}

de Groot, John ^{[10
]}

Gilbert, Mark R. ^{[11
]}

Huang, Raymond ^{[2
,12
]}

Lassman, Andrew B. ^{[13
,14
,15
]}

Mehta, Minesh ^{[16
]}

Molinaro, Annette M. ^{[17
]}

Preusser, Matthias ^{[18
]}

Rahman, Rifaquat ^{[19
]}

Shankar, Lalitha K. ^{[20
]}

Stupp, Roger ^{[21
,22
,23
,24
]}

Villanueva-Meyer, Javier E. ^{[25
,26
]}

Wick, Wolfgang ^{[27
,28
]}

Macdonald, David R. ^{[29
,30
]}

Reardon, David A. ^{[1
,2
]}

Vogelbaum, Michael A. ^{[31
,32
]}

Chang, Susan M. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands

[4] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Tumor Program, Los Angeles, CA USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, UCLA Brain Tumor Imaging Lab, Los Angeles, CA USA

[6] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[7] Univ Zurich, Zurich, Switzerland

[8] Mayo Clin, Dept Oncol, Rochester, MN USA

[9] Duke Univ, Med Ctr, Dept Radiol, Durham, NC USA

[10] Univ Calif San Francisco, Dept Neurosurg, Div Neurooncol, San Francisco, CA USA

[11] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[12] Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA

[13] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurol,Div Neuroradiol, New York, NY USA

[14] Columbia Univ, Irving Inst Clin & Translat Res, Vagelos Coll Phys & Surg, New York, NY USA

[15] New York Presbyterian Hosp, New York, NY USA

[16] Miami Canc Inst, Miami, FL USA

[17] Univ Calif San Francisco, Dept Neurol Surg, Div Biomed Stat & Informat, San Francisco, CA USA

[18] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

[19] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA

[20] NCI, Clin Trials Branch, Canc Imaging Program, NIH, Bethesda, MD USA

[21] Northwestern Univ, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr, Chicago, IL USA

[22] Northwestern Univ, Dept Neurol Surg, Chicago, IL USA

[23] Northwestern Univ, Dept Neurol, Chicago, IL USA

[24] Northwestern Univ, Div Hematol Oncol, Chicago, IL USA

[25] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA

[26] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA

[27] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany

[28] German Canc Res Ctr, ClinicalCooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany

[29] Western Univ, Dept Clin Neurol Sci, London, ON, Canada

[30] Western Univ, Dept Oncol, London, ON, Canada

[31] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA

[32] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, Tampa, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 33期

关键词：

MALIGNANT GLIOMA; GLIOBLASTOMA; PSEUDOPROGRESSION; PROGRESSION; RECOMMENDATIONS; RECIST; PET;

D O I：

10.1200/JCO.23.01059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria.METHODSInformed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0).RESULTSWe recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment.CONCLUSIONThe revised RANO 2.0 criteria refine response assessment in gliomas.

引用

页码：5189 / +

页数：15

共 50 条

[1] RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, P.
Van Den Bent, M.
Youssef, G.
Cloughesy, T.
Ellingson, B.
Weller, M.
Galanis, E.
Barboriak, D.
DeGroot, J.
Gilbert, M.
Huang, R.
Lassman, A.
Mehta, M.
Molinaro, A.
Preusser, M.
Rahman, R.
Shankar, L.
Stupp, R.
Sul, J.
Villanueva-Meyer, J.
Wick, W.
Macdonald, D.
Reardon, D.
Vogelbaum, M.
Chang, S.
NEURO-ONCOLOGY, 2023, 25 : 21 - 21
[2] RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults
Wen, Patrick Y.
Van Den Bent, Martin J.
Youssef, Gilbert
Cloughesy, Timothy Francis
Ellingson, Benjamin M.
Weller, Michael
Galanis, Evanthia
Barboriak, Daniel
De Groot, John Frederick
Gilbert, Mark R.
Huang, Raymond Yi-Kun
Lassman, Andrew B.
Mehta, Minesh P.
Molinaro, Annette
Preusser, Matthias
Shankar, Lalitha Krishna
Wick, Wolfgang
Reardon, David A.
Vogelbaum, Michael A.
Chang, Susan Marina
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future
Wen, Patrick Y.
van den Bent, Martin
Vogelbaum, Michael A.
Chang, Susan M.
NEURO-ONCOLOGY, 2024, 26 (01) : 2 - 4
[4] A Neuroradiologist?s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults
Ellingson, Benjamin M.
Sanvito, Francesco
Cloughesy, Timothy F.
Huang, Raymond Y.
Villanueva-Meyer, Javier E.
Pope, Whitney B.
Barboriak, Daniel P.
Shankar, Lalitha K.
Smits, Marion
Kaufmann, Timothy J.
Boxerman, Jerrold L.
Weller, Michael
Galanis, Evanthia
de Groot, John
Gilbert, Mark R.
Lassman, Andrew B.
Shiroishi, Mark S.
Nabavizadeh, Ali
Mehta, Minesh
Stupp, Roger
Wick, Wolfgang
Reardon, David A.
Vogelbaum, Michael A.
van den Bent, Martin
Chang, Susan M.
Wen, Patrick Y.
AMERICAN JOURNAL OF NEURORADIOLOGY, 2024,
[5] A Neuroradiologist?s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults
Ellingson, Benjamin M.
Sanvito, Francesco
Cloughesy, Timothy F.
Huang, Raymond Y.
Villanueva-Meyer, Javier E.
Pope, Whitney B.
Barboriak, Daniel P.
Shankar, Lalitha K.
Smits, Marion
Kaufmann, Timothy J.
Boxerman, Jerrold L.
Weller, Michael
Galanis, Evanthia
Groot, John de
Gilbert, Mark R.
Lassman, Andrew B.
Shiroishi, Mark S.
Nabavizadeh, Ali
Mehta, Minesh
Stupp, Roger
Wick, Wolfgang
Reardon, David A.
Vogelbaum, Michael A.
van den Bent, Martin
Chang, Susan M.
Wen, Patrick Y.
AMERICAN JOURNAL OF NEURORADIOLOGY, 2024, 45 (12) : 1846 - 1856
[6] Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
van den Bent, M. J.
Wefel, J. S.
Schiff, D.
Taphoorn, M. J. B.
Jaeckle, K.
Junck, L.
Armstrong, T.
Choucair, A.
Waldman, A. D.
Gorlia, T.
Chamberlain, M.
Baumert, B. G.
Vogelbaum, M. A.
Macdonald, D. R.
Reardon, D. A.
Wen, P. Y.
Chang, S. M.
Jacobs, A. H.
LANCET ONCOLOGY, 2011, 12 (06): : 583 - 593
[7] Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas
Youssef, Gilbert
Wen, Patrick Y.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2024, 24 (02) : 17 - 25
[8] Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas
Gilbert Youssef
Patrick Y. Wen
Current Neurology and Neuroscience Reports, 2024, 24 : 17 - 25
[9] UPDATED RESPONSE ASSESSMENT CRITERIA FOR HIGH-GRADE GLIOMAS (HGG): REPORT FROM THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) WORKING GROUP
van den Bent, M.
MacDonald, D.
Chang, S.
Vogelbaum, M. A.
Wen, P. Y.
NEURO-ONCOLOGY, 2010, 12 : 3 - 3
[10] RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES
Wen, P. Y.
Lee, E. Q.
Van den Bent, M.
Soffieti, R.
Bendszus, M.
Mehta, M.
Baumert, B.
Vogelbaum, M.
Chang, S. M.
Lin, N. U.
NEURO-ONCOLOGY, 2014, 16

← 1 2 3 4 5 →